Mylan Pharmaceuticals Inc reports final approval for Granisetron Hydrochloride Tablets from FDA

Mon. February 04, 2008; Posted: 04:23 AM

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

Feb 04, 2008 (M2 EQUITYBITES via COMTEX) -- MYL | news | PowerRating | PR Charts -- Mylan Inc (NYSE: MYL), a generic and speciality pharmaceutical company, said on 1 February that Mylan Pharmaceuticals Inc has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Granisetron Hydrochloride Tablets, 1 mg (base).

The company said the product will be shipped with immediate effect. Granisetron Hydrochloride Tablets are reportedly the generic version of Roche's Kytril Tablets, which had U.S. sales of around USD89m for the 12 months ending 30 September 2007, according to IMS Health.

Comments on this story may be sent to admin@m2.com

For full details on Ims Health Inc (RX) click here. Ims Health Inc (RX) has Short Term PowerRatings of 5. Details on Ims Health Inc (RX) Short Term PowerRatings is available at This Link.

Morning Coffee with TradingMarkets -- Free Newsletter

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.